Mind Medicine (MindMed) (MNMD) Stock Analysis & Winston Score
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdra
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (1/20)
- Cash Flow: Data not available (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $20.69
Market Cap: $1.6B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

